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The systemic vasculitides include a heterogenous group of diseases 
characterised by inflammation of blood vessels. Evidence for treatment in this 
group of patients is limited due to rarity of the diseases, incomplete 
understanding of the pathogenesis and lack of appropriate biomarkers. In the 
last 20 years international collaboration and networking led to clinical trials in a 
select sub-group of patients with systemic vasculitis. Anti-neutrophil 
cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most studied 
sub-group. This article discusses the treatment options of AAV in light of 
evidence from clinical trials.  
 
Treatment of AAV, which includes an induction and a maintenance phase, is 
dependent on the severity of the disease. Oral or intravenous cyclophosphamide 
and high dose glucocorticoids are considered to be standard of care for induction 
of remission in AAV patients with generalised disease. Latest evidence supports 
rituximab as an alternative to cyclophosphamide especially in relapsing patients 
and is increasingly being used in patients who cannot have cyclophosphamide. 
Plasma exchange, and intravenous immunoglobulins (IVIG) are used as 
adjunctive therapies for induction.  
 
Azathioprine or methotrexate (in non-renal patients) is considered to be the 
choice for remission maintenance, whilst mycophenolate mofetil is reserved for 
patients who cannot tolerate either of them. Rituximab is also being increasingly 
used for remission maintenance in relapsing patients. Even though an enormous 
progress has been made in the outlook of patients with AAV, a number of 




Systemic vasculitis is characterised by inflammation and necrosis of blood vessel 
walls, leading to occlusion of the vessel lumen, tissue damage and eventually to 
organ failure. Vasculitis may be primary in origin or secondary to another 
autoimmune process such as systemic lupus erythematosus or rheumatoid 
arthritis, infections, neoplasia or drugs. Vasculitides are usually classified 
according to the predominant size of the blood vessels involved. Research into 
primary vasculitides has been difficult due to lack of biomarkers except for a 
sub-group called antineutrophil cytoplasmic antibody (ANCA) associated 
vasculitis (AAV). AAV is classified under the small vessel vasculitis sub-group of 
vasculitides in the latest Chapel Hill Consensus classification system1. This article 
will review the treatment options in AAV in light of past, current and future 
clinical trials.  
 
ANCA associated vasculitis (AAV): 
 
AAV, characterised by the presence of autoantibodies to neutrophil cytoplasmic 
antigens, proteinase 3 (PR3) and myeloperoxidase (MPO) (ANCA) typically 
involves small blood vessels of the respiratory tract and kidneys. It encompasses 
three distinct clinical syndromes: granulomatosis with polyangiitis (GPA, 
previously Wegener’s granulomatosis), microscopic polyangiitis (MPA) and 
eosinophilic granulomatosis with polyangiitis (eGPA, previously Churg Strauss 
Syndrome). GPA is commonly associated with PR3 ANCA (66% of the patients)2 
whilst MPO is associated with MPO-ANCA (58% of the patients)2. Only 40% of 
patients with eGPA are ANCA positive3.  
 
Patients with GPA typically present with granulomatous inflammation, 
commonly of the upper airways and lungs. Renal involvement is seen more often 
in MPA, but can also occur in GPA.  Patients with eGPA typically have a prodrome 
of asthma for few years before presenting with systemic vasculitis symptoms. 
The pathogenetic mechanisms of eGPA differ significantly from that of GPA or 
MPA and eGPA is clinically distinct from GPA and MPA.  
 
ANCA vasculitis can present with a wide spectrum of disease activity and it is 
important to customise the treatment depending on the disease activity. 
European league against rheumatic diseases (EULAR) recommends (Table 1) 4 
using either European vasculitis study group (EUVAS) or Wegener’s 




Obtained with permission from BMJ publishing group, Hellmich, B. et al. Ann. 
Rheum. Dis. 66, 605–617 (2007). 
 
Most clinical trials have not differentiated between the clinical subtypes of AAV 
disease either based on ANCA specificity or clinical syndrome (GPA and MPA or 
PR3 and MPO AAV). However this may be important for future studies given the 
genetic evidence5 suggesting a robust genetic association in relation to antibody 
specificity when compared to clinical syndromes (PR3-ANCA disease is 
associated with HLA- DP, SERPINA1 and PRTN3, while MPO-ANCA disease is 
associated with HLA-DQ). Also it is known that patients with PR3 disease have a 
different phenotype associated with increased risk of relapse6 and patients with 
renal PR3-AAV are more likely to have a dramatic deterioration in kidney 
function but respond better to treatment compared to those with MPO-AAV7.  
 
Pathogenesis of AAV: 
The pathogenesis of AAV  (Figure 1)8 is not completely known, however there 
has been progress in our understanding in the last two decades. Genetic 
susceptibility along with environmental exposures to agents such as infections 
(Staphylococcus aureus), silica or drugs is implicated in the disease process. 
Dysfunctional innate and adaptive immune systems also play a role in its 
pathogenesis. ANCA produced by B cells may be pathogenic as shown in animal 
models9. B cell activating factor (BAFF) is elevated in AAV patients10 and this 
may be an important therapeutic target. Neutrophils activated by ANCA 
degranulate and release reactive oxygen species (ROS), pro-inflammatory 
cytokines and complement activators, leading to endothelial damage. 
Inflammation is also promoted by the presence of increased numbers of pro-
inflammatory CD4+ effector memory cells11, IL17 producing Th17 cells12, IL21 
producing cells and a reduction in the number of regulatory cells. The alternative 
complement pathway is triggered by activated neutrophils and damaged 
endothelium13. C5a, a by-product of the complement activation is a powerful 
neutrophil chemo-attractant, which recruits more neutrophils to the site14. 
Therapies in AAV target various aspects of these pathogenic mechanisms in 






Obtained with permission from Nature Publishing Group, Furuta et al, Kidney Int. 
84, 244–9 (2013). 
Treatment in AAV:  
 
The use of cyclophosphamide and glucocorticoids as induction therapy for AAV, 
has improved the survival rates from 20% to well over 80% at 2 years15. 
However, longterm follow up of these patients revealed significant toxicity 
associated with the use of cyclophosphamide as well as high levels of morbidity 
associated with chronic glucocorticoid exposure. This, along with a high relapse 
rate (50%) has provided an impetus to look for less toxic and more efficacious 
treatment options. Strategies such as pulsed intravenous dosing, switching to 
less toxic agents after induction of remission and avoidance of 
cyclophosphamide in less severe disease were used. Rituximab, a B cell depleting 
agent, in the last decade has been shown to be non-inferior to cyclophosphamide 
and is now licensed for use of remission induction. Currently strategies to 
minimise glucocorticoid exposure are also being explored. 
 
Treatment of AAV typically includes two distinct phases, an induction phase (3 to 
6 months), to gain rapid control of disease activity and a maintenance phase (18 
to 24 months), to maintain remission and prevent relapses, using less toxic 
agents.  
 
Drugs used for induction of remission: 
1. Cyclophosphamide: 
Cyclophosphamide, an alkylating agent, inhibits DNA replication by 
alkylating guanidine nucleotides. Its mechanism of action is poorly 
understood in vasculitis but it is thought to exert toxic effect on both 
resting and dividing lymphocytes.  Introduction of cyclophosphamide in 
1970’s has remarkably improved the survival of patients with generalised 
AAV.  Even though it is considered to be standard treatment for induction 
in generalised AAV, its prolonged use is associated with increased risk of 
infections, cytopenias, infertility, bladder cancer, cardio-vascular risk and 
myelodysplasia.  
 
Cyclophosphamide is usually given either as oral or pulsed therapy for 
three to six months and is replaced by less toxic drugs after achieving 
remission. Cyclophosphamide when administered intravenously as 
pulsed therapy may lead to reduction in cumulative dose and consequent 
reduction in toxicity. This strategy was assessed by the CYCLOPS trial. 
149 patients with generalised AAV were randomised to receive 
intravenous cyclophosphamide [15mg/kg every 2 to 3 weeks] or daily 
oral cyclophosphamide [2mg/kg], which were continued for 3 months 
after achieving remission. This trial showed that the time to remission 
(hazard ratio, 1.098 [95% CI, 0.78 to 1.55]; p = 0.59) and the proportion 
of patients that achieve remission by 9 months (88.1% vs. 87.7%) was 
similar in both the groups16. The cumulative dose was lower in the pulse 
group (15.9 g [IQR 11 to 22.5 g] vs. 8.2 g [IQR 5.95 to 10.55 g]; P< 0.001) 
and this was associated with less incidence of leukopenia (hazard ratio, 
0.41 [CI, 0.23 to 0.71]). However longterm analysis of this cohort with a 
median of 4.3 years, showed that the risk of relapse was lower in the oral 
than in the intravenous arm (39.5% versus 20.8%, HR=0.50, 95% CI 0.26 
to 0.93; p=0.029)17. Nevertheless, there was no difference in terms of 
mortality, renal function, end stage renal failure or adverse events 
between the two groups. In this trial, in order to reduce toxicity, the dose 
of cyclophosphamide was adjusted according to age and renal function 
(Table 2) and is now considered to be a standard practice. 
 
Table 2: IV pulsed cyclophosphamide dose (per pulse mg/kg) 




<60 15 12.5 
60-70 12.5 10 
>70 10 7.5 
 
A retrospective analysis of EUVAS trials18 showed that oral 
cyclophosphamide use was associated with lower relapse risk when 
compared to other agents even though they help to achieve similar 




B cells play an important role in the pathogenesis of AAV. Rituximab, a 
chimeric monoclonal antibody depletes B cells by ligation with surface 
expressed CD20 antigens. Two randomised controlled trials, RAVE19 and 
RITUXVAS20 have shown that rituximab is non-inferior to 
cyclophosphamide for induction of remission in AAV and is now licensed 
for induction therapy. There was no difference in safety or adverse 
events. 
 
These two trials had some differences. RITUXVAS (n=44) included new 
patients with severe renal disease whereas RAVE (n=197) included new 
as well as relapsing patients with well-preserved kidney function. Oral 
cyclophosphamide was used as a comparator in RAVE, whilst pulsed 
cyclophosphamide was used in RITUXVAS. In both trials rituximab was 
administered as four infusions of 375mg/m2 body surface area, however 
in RITUXVAS two or three cycles of cyclophosphamide was given in 
addition to rituximab. Prednisolone was tapered and stopped by 5 
months in RAVE trial whilst it was reduced to 5mg by 6 months and 
continued for the rest of the trial in RITUXVAS trial. Neither trial 
continued with maintenance immunosuppression in the rituximab group. 
The primary endpoint in RAVE was the absence of disease activity 
(Birmingham Vasculitis Activity score for Wegener’s, BVAS/WG of 0) and 
completion of prednisolone withdrawal by 6 months. In RITUXVAS 
sustained remission, defined, as absence of any disease activity for at least 
6 months was the primary endpoint. 
 
In the RAVE trial (1:1 randomisation), the primary outcome at 6 months 
was achieved by 64% in the rituximab arm compared to 53% in the 
control arm and it met the criterion for non-inferiority (p<0.001). 
However patients with relapsing disease at baseline achieved better 
response rate (67% versus 42%, p = 0.01). This effect persisted even after 
adjusting for ANCA type and clinical site (OR: 1.40, 95% CI, 1.03 to 1.91, p 
= 0.03). At 18 months 39% in the rituximab arm and 33% in the control 
arm maintained complete remission21. This trial did not show a difference 
in the number of total or serious adverse events between the two arms. 
 
In the RITUXVAS trial (randomised 3:1 to rituximab or 
cyclophosphamide), the primary outcome of sustained remission 
occurred in 76% in rituximab arm compared to 82% in the control arm, p 
= 0.68. Again no difference in safety was observed between the two 
groups. Long-term analysis of these patients showed that at 24 months 
remission was maintained in 61% in rituximab arm compared to 64% in 
the cyclophosphamide arm22.  
 
It was evident from the above two trials that the relapse risk after 
induction of remission with rituximab remains high and most patients 
would need subsequent maintenance therapy to prevent relapses. Also 
the adverse event rates in both trials were similar to the conventional 
therapy with cyclophosphamide suggesting no benefit in choosing 
rituximab over cyclophosphamide except in patients with relapsing 
disease. It can be used in patients who are intolerant of 
cyclophosphamide, patients in the reproductive age group or who had 
significant exposure to cyclophosphamide in the past with or without 
associated toxicity. Its role as monotherapy (with glucocorticoids) in 
severe disease is not established and there is no consensus on the 
appropriate dosing regimen. These questions need to be addressed in 
future trials. A post-hoc analysis of the RAVE trial has concluded that PR3-
ANCA positive patients were more likely to obtain a remission of their 





Methotrexate competitively inhibits the dihydrofolate reductase enzyme 
inhibiting the synthesis of DNA, RNA and proteins. It inhibits T cell 
activation and down regulates B cells. Methotrexate at a dose of 15mg to 
25mg per week (oral or subcutaneously) is used as an alternative to 
cyclophosphamide and rituximab therapy in patients with early systemic 
disease without significant renal involvement. 
 
The NORAM trial (n=100) 23 compared oral methotrexate to oral 
cyclophosphamide for remission induction in newly diagnosed AAV 
patients with non-severe disease.  The remission rate at 6 months in 
methotrexate arm was not inferior to that in cyclophosphamide arm 
(89.8% versus 93.5%, p = 0.041). It was shown that in the methotrexate 
arm, remission was delayed in patients with pulmonary disease or 
patients with extensive disease. Also the time to remission was longer in 
the methotrexate arm. 70% of the patients in methotrexate arm relapsed 
at 18 months compared to 46% in the control arm. This higher rate of 
relapse in both arms was influenced by the withdrawal of 
immunosuppression by 12 months.  
 
Longterm analysis of data from this trial24 (median 6 years) showed that 
methotrexate treatment was associated with prolonged use of steroids (p 
= 0.005) and that was associated with less effective disease control. There 
was no difference in the adverse event profile between the two 
treatments. There were less cases of leucopoenia with methotrexate but 
more cases of liver dysfunction. 
 
4. Mycophenolate mofetil (MMF): 
 
Mycophenolate mofetil (MMF) is used routinely in systemic lupus 
erythematosus as an induction agent and evidence from a retrospective 
case series25 and a prospective pilot trial26 suggested benefit in AAV as 
well. The advantages of using MMF include its selective 
immunosuppressive effect; less toxicity and short duration of action when 
compared to cyclophosphamide and it can be used in renal failure without 
dose adjustments.  
 
MYCYC27, a randomised controlled trial comparing MMF with 
cyclophosphamide for induction therapy in AAV has finished recruiting. 
In this trial, newly diagnosed AAV patients were assigned to receive up to 
6 months of induction therapy with either MMF 2 to 3g/ day (n=70) or 6-
10 pulses of IV cyclophosphamide (n=70). In the preliminary analysis27 
response rates between MMF and cyclophosphamide based regimens 
were similar at six months but there was an excess of subsequent 
relapses in PR3-ANCA patients who initially received MMF. Thus MMF 
may be an alternative induction agent to cyclophosphamide for MPO-
ANCA positive patients.  
5. Glucocorticoids: 
There is little direct evidence to guide glucocorticoid dosing, despite their 
use in induction therapy for many years. Most physicians give 1mg/kg 
daily oral prednisolone (after pulsed methyl-prednisolone, e.g. 1g daily 
for 3 days in patients with severe disease) with an aim to wean to the 
lowest possible dose by 6 months (e.g. 5mg/day or less by 6 months). 
Even though steroids help to suppress inflammation and gain rapid 
control, multiple co-morbidities associated with high dosage, is driving 
research to reduce or replace their usage. 
 
Two studies are exploring glucocorticoid dosing:  PEXIVAS28, (discussed 
below), is comparing standard high dose against reduced dose 
glucocorticoids (0.5mg/kg/day) as a component of the induction regimen 
for patients with severe AAV. The CLEAR trial29 is a phase 2 randomised 
controlled trial (discussed below) designed to evaluate the safety and 
efficacy of CCX168, an oral C5a inhibitor as a replacement to standard 
dose steroids in AAV patients with mild to moderate disease activity 
treated with cyclophosphamide.  
 
Adjunctive therapies: 
6. Plasma exchange: 
Plasma exchange in AAV may help in rapid induction of severe disease by 
removing pathogenic ANCA and mediators of inflammation, however its 
mechanism of action is not clear. Small randomised studies and a larger 
RCT, MEPEX have shown short-term benefit in reducing the risk of ESRD. 
 
In the MEPEX trial 137 new AAV patients with renal involvement 
(creatinine >500) were randomised to receive either 7 plasma exchanges 
(PLEX arm) or three doses of IV methylprednisolone in addition to 
standard therapy. At 3 months, 69% in the PLEX arm were independent 
of dialysis compared to 49% in the IV methylprednisolone arm (RR: 20%, 
95% CI: 18 to 35%, p = 0.02). At 12 months the risk for progression to 
ESRD was lower in the PLEX arm (RR: 24%, 95% CI: 6.1 to 41%).  
 
Long-term data analysis of this cohort at a median of 3.95 years showed 
that the advantage of better kidney function at 12 months with plasma 
exchange was not carried forward. The hazard ratio for PLEX compared 
to IV methyl prednisolone was 0.81(95% CI 0.53 – 1.23, p = 0.32) for a 
composite outcome of death or ESRD30.  
 
The MEPEX study was not powered to detect this change and the larger 
PEXIVAS trial currently recruiting patients will hopefully provide more 
answers. This trial has a two-by-two factorial design to answer two 
important questions: 1) does adjunctive plasma exchange improve the 
time to composite endpoint of all-cause mortality and end stage renal 
disease? 2) Is a more rapid glucocorticoid reduction as efficacious, but 
safer than a standard regimen? In this open label study, 700 AAV patients 
with severe disease will be randomised to receive 1) adjunctive plasma 
exchange or no plasma exchange and 2) high dose steroids or reduced 
dose steroids, in addition to standard induction therapy with 
cyclophosphamide or rituximab. Patients are followed up for a maximum 
of 7 years and a minimum of 1 year. 
7. IV methylprednisolone: 
Most patients presenting with severe disease receive up to 3g of 
intravenous methyl prednisolone over a period of 3 days. There is no 
established evidence for the same. MEPEX trial tested intravenous 
methylprednisolone against plasma exchange, however in reality both are 
used simultaneously. 
8. Intravenous immunoglobulins (IVIG): 
IVIG is used as an adjuvant therapy in patients with severe disease, 
refractory disease or patients in whom standard therapy is 
contraindicated such as with severe infections where 
immunosuppression is deemed unsuitable. A Cochrane review31 
identified only one randomised placebo controlled trial32 in 34 previously 
treated AAV patients with persistent disease activity. 17 patients in the 
IVIG arm received 1 course of 2g/kg IVIG and the other group received 
placebo. Even though IVIG caused reduction in disease activity (MD 2.30; 
95% Confidence interval (CI) 1.12 to 3.48, P < 0.01), the effects did not 
last for more than 3 months. Also there were more adverse events in the 
IVIG group (relative risk (RR) 3.50; 95% CI 1.44 to 8.48, P < 0.01). Given 




Relapses are common without maintenance therapy. In a prospective 
study, conducted by National Institute for Health, treatment with oral 
steroids and oral cyclophosphamide for prolonged periods, even though 
resulted in 75% complete remission rate had a 50% relapse rate33. The 
optimal duration of maintenance therapy is not known but conventionally 
given for a period of 18 to 24 months34. The high relapse rate seen in the 
NORAM trial (relapse rate of 69.5% in the methotrexate arm and 46.5% in 
the cyclophosphamide arm) where maintenance therapy was stopped by 
12 months, suggests that prolonged therapy may be needed. The REMAIN 
trial35, has reported a reduced relapse risk after 24 months if azathioprine 
and prednisolone are continued. ANCA positivity at 24 months was a 
predictor of subsequent relapse.  
1. Azathioprine: 
 
Azathioprine is an anti-metabolite and a purine analogue that blocks the 
synthesis of DNA inhibiting the proliferation of cells. Before the 
introduction of azathioprine, treatment with oral steroids and 
cyclophosphamide for prolonged periods was the norm. 42% of these 
patients had treatment related side effects such as serious infections, 
leucopoenia, haemorrhagic cystitis, risk of bladder cancer, infertility and 
amenorrhoea.  
 
The CYCAZAREM trial (n=155) 36 demonstrated that after remission 
induction, cyclophosphamide can be switched to azathioprine 
maintenance at a dose of 2mg/kg/day for relapse prevention (relapses in 
azathioprine versus oral cyclophosphamide groups at 18 months: 15.5% 
versus 13.7%, p = 0.65). This strategy may reduce the adverse affects 
seen with prolonged use of cyclophosphamide. Serious adverse events in 
both groups were similar (11% versus 10%, p = 0.94) in the short term.  
Long term follow up of these patients showed that there is a trend 
towards poorer outcomes (relapse risk, ESRD and death) in the 
azathioprine group but this was not statistically significant37. 
Azathioprine use is associated with myelosuppression, increased risk of 
infections, hepatotoxicity, increased incidence of skin cancers and 
lymphoma but is considered safer than cyclophosphamide and, along 
with methotrexate, is the first choice for maintenance therapy. 
2. Rituximab: 
Rituximab is being increasingly used for remission maintenance in 
selected AAV patients who are at high risk of relapse or who relapsed on 
other maintenance therapies. MAINRITSAN trial (n=115)38 that 
compared rituximab maintenance therapy with azathioprine in new or 
relapsing AAV patients after cyclophosphamide induction, has 
confirmed the superiority of rituximab for maintenance therapy. 
Patients in the rituximab arm received 1000mg rituximab at 6 months 
then 500mg every six months for three further doses whilst patients in 
the azathioprine arm received 2mg/kg/day azathioprine for 22 months. 
At 28 months, there were relapses in 5% of the patients in the rituximab 
arm compared to 29% in the azathioprine arm (hazard ratio of 6.61 
[95% CI 1.56 to 27.96, p = 0.002]). The frequencies of adverse events did 
not differ between the two groups. 
 
The RITAZERAM trial (n=190)39 is testing the hypothesis that rituximab 
is superior to azathioprine in patients with relapsing disease who 
achieve remission following rituximab induction. Rituximab 1g is 
administered every 4 months from randomisation until month 20 (5 
doses) in the rituximab arm whilst the other arm receives oral therapy 
(azathioprine, methotrexate or mycophenolate mofetil). 
 
A retrospective analysis40 of patients that received six monthly repeat 
dose rituximab maintenance for a two year period, showed that 42% of 
the patients who were in remission at the end of the treatment period 
relapsed at a median of 34.4 months after the last dose. The risk of 
relapse was predicted by PR3-ANCA positive disease, return of B cells 
within 12 months after the last dose of rituximab and a switch from 
ANCA negativity to positivity. 
 
The optimal maintenance regimen using rituximab is not known and is 
the subject of current investigations. MAINRITSAN 2 trial41 is testing two 
different dosing regimens for maintenance, one based on fixed dosing 
every six months and the other based on the return of B cells and/or re-
appearance of ANCA or rise in ANCA titres. The MAINRITSAN 3 trial42 is 
comparing the effect of rituximab therapy for 46 months against the 
conventional therapy for 18 months, as the relapse rate after 
discontinuing therapy at 18 months was high at 30% in the 
MAINRITSAN trial. 
 
The long-term affects of rituximab therapy are not known and registry 
data would enable us to garner this information. Rituximab use may be 
associated with increased risk of infections (serious including PML), 
acquired hypogammaglobulinaemia and late onset neutropenia. These 
risks should be weighed against potential benefit before embarking on 




Methotrexate can be used as an alternative to azathioprine to maintain 
remission in patients with adequate renal function (creatinine 
<150umol/L or 1.8mg/dl). WEGENT trial (n= 126)43 compared 
methotrexate (at a dose of 0.3mg/kg/week progressively increased to 
25mg/week) against azathioprine (2mg/kg/day) for maintenance 
therapy in AAV patients that achieved remission with cyclophosphamide 
and steroids. These two agents were shown to be similar in terms of 
remission maintenance (relapses seen in 33% in methotrexate arm 
compared to 36% in azathioprine arm, p = 0.71) and adverse events 
(hazard ratio for methotrexate, 1.65 [95% confidence interval, 0.65 to 
4.18; P = 0.29]). Methotrexate use can be associated with myelotoxicity, 
hepatotoxicity, nephrotoxicity, pulmonary toxicity and hypersensitivity 
reactions. 
 
4. Mycophenolate mofetil: 
Mycophenolate mofetil, an anti-proliferative agent is another alternative 
to azathioprine to maintain remission in AAV patients. However it was 
shown to be less effective than azathioprine in maintaining remission 
and is used as a second line agent. 
IMPROVE trial (n=174)44 compared mycophenolate mofetil (2g/day) 
against azathioprine (2mg/kg/day) in maintaining remission after 
induction of remission with cyclophosphamide and steroids. Relapses 
were more common in the mycophenolate arm (55% versus 37.5%, 
hazard ratio for mycophenolate 1.69, 95% CI [1.06-2.70, p=0.03]). 
Adverse events did not differ between the two arms. In view of this 
result mycophenolate is considered in patients in whom azathioprine 
and methotrexate are contra-indicated. 
5. Co-trimoxazole: 
 As respiratory tract infections may predispose patients with GPA to 
relapses, co-trimoxazole is used in some patients to maintain remission. 
In a randomised placebo controlled trial (n=81) 45 conducted in GPA 
patients who are in remission, 24 months treatment with co-trimoxazole 
(960mg bd) was compared against placebo in preventing relapses. Co-
trimoxazole use resulted in less relapses (18% versus 40%; relative risk 
of relapse 0.40) especially in upper airways disease and was also 
identified as an independent factor associated with prolonged disease-
free survival. As this drug is well tolerated and given it’s anti-
staphylococcal action it would seem logical to use this drug in remission 
maintenance of patients with GPA and upper airway disease.  
6. Glucocorticoids: 
Glucocorticoid dosing practices vary widely and there is no consensus. 
Typically prednisolone dose is tapered to 15mg/day by 3 months and to 
5mg/day or less by 6 months. A meta-analysis46 of 13 heterogenous 
vasculitis studies showed that patients on longer courses of steroids are 
likely to have fewer relapses (14% in the prolonged steroid group 
versus 43% in the other group). This study was limited by the fact that 
the comparability of the trials was poor and there may have been many 
factors other than steroid dose that lead to relapses. 
 
TAPIR47 is a randomized controlled trial in patients with a diagnosis of 
GPA who are in remission to evaluate the effects of using low-dose 
glucocorticoids (5 mg/day of prednisolone) as compared to stopping 
glucocorticoid treatment entirely (0 mg/day of prednisolone) on rates of 
disease relapse/disease flares. LoVAS trial48 is comparing low dose 
prednisolone (0.5mg/kg/day tapered to 0mg within six months) with 
rituximab induction against standard dose prednisolone (1mg/kg/day 
tapered to 10mg/day within six months) with rituximab induction in 
patients with a new diagnosis of AAV. 
 
7. Anti-TNF agents: 
The WGET trial49 did not show benefit in adding etanercept (soluble TNF 
receptor) to standard therapy with cyclophosphamide and steroids in 
maintaining remission. Its use was associated with increased incidence 
of solid cancers. This treatment option is not recommended. A phase IIb 
trial of infliximab as a component of remission induction therapy for 
new or refractory patient subgroups had acceptable safety and 
suggested a steroid sparing effect of infliximab. 
Treatment of eosinophilic granulomatosis with polyangiitis 
(EGPA): 
  
Eosinophilic granulomatosis with polyangiitis (EGPA) shares many 
clinical features with GPA and MPA but has received much less clinical 
trial activity. The French Vasculitis study group has identified five 
prognostic factors: 1) creatinine >140umol/L 2) proteinuria (>1g/day) 3) 
gastrointestinal tract involvement 4) cardiomyopathy 5) central nervous 
system involvement. These five factors together make five factor score 
(FFS)50.  Patients with less severe disease (FFS=0) do well compared to 
patients with more severe disease (FFS ≥ 1).  
 
A European taskforce on EGPA has issued consensus guidelines for 
evaluation and management of EGPA51. Glucocorticoids are the primary 
choice of therapy to treat EGPA. Patients with severe disease receive 
methylprednisolone. Steroids are tapered over a period of 6 months to 
about 0.15mg/kg/day or lowest dose possible to maintain remission. 
There are no trials looking at the best dosing strategy for steroids in 
EGPA. 
 
In a prospective randomised controlled trial52, patients with less severe 
disease (Five factor score, FFS = 0), who were treated with steroids alone 
remission was achieved in most patients (93%) but relapses were 
common (35%). Azathioprine or cyclophosphamide was effective in 
treating steroid resistant disease. Cyclophosphamide is considered first 
line agent to treat severe disease. In a trial53 in EGPA patients with poor 
prognosis factors (FFS ≥ 1), it was shown that 12 cyclophosphamide 
pulses were better at controlling the disease when compared to 6 pulses 
(relapses 62% in 12 pulses versus 85.7% in 6 pulses). Current strategies 
to maintain remission are similar to those of GPA and MPA. There is little 
evidence to recommend one treatment over others. Rituximab was shown 
in a retrospective study54 to be effective in achieving remission even in 
refractory and relapsing patients and is used for induction and 
maintenance of remission. EGPA is considered classically to be a Th-2 
mediated disease with elevated levels of IL-4, IL-13 and IL-555. 
Mepolizumab is a humanized monoclonal antibody against IL-5, which 
was recently licensed for use in chronic eosinophilic asthma, is being 
tested to treat EGPA (see below). 
 
  
Current studies using newer drugs in vasculitis: 
 
CLEAR trial (CCX168): 
CCX168 is an oral inhibitor of C5a, an anaphylotoxin produced as a by-
product of complement system activation. C5a primes neutrophils for 
ANCA induced activation14. The CLEAR trial is a phase 2 randomised 
controlled trial designed to evaluate the safety and efficacy of CCX168 
compared to standard dose steroids and cyclophosphamide in AAV 
patients with mild to moderate disease activity and an eGFR 
>20ml/minute29.  The purpose of this trial is to see if CCX168 can induce 
remission by reducing or avoiding glucocorticoids from the regimen.  
Preliminary results did show an improvement in renal function (eGFR 
improved by 6.8 mL/min/1.73 m2 over 12 weeks), urinary albumin 
creatinine ratio (mean decrease up to 63% over 12 weeks), and urinary 
MCP-1 to creatinine ratio (up to 72% decrease over 12 weeks)56. This was 
against a background of reduced or no oral glucocorticoids.. 
 
BREVAS trial (Belimumab):  
 
Belimumab is a monoclonal antibody directed against B cell activating 
factor (BAFF). BAFF, a member of TNF family is a crucial factor that 
promotes the B cell survival and transition from immature to mature B 
cells. Elevated levels of BAFF are found in patients with GPA and there is 
accruing data to support that neutralization of BAFF would help to 
control the autoimmune process. Belimumab has been approved recently 
for use in the treatment of lupus. Currently BREVAS57 trial (n= 400) 
comparing belimumab with azathioprine against standard therapy for 
maintenance of remission is on going. 
 
ABROGATE trial (Abatacept): 
 
Abatacept is a fusion protein with CTLA-4 domain, which binds to CD80 
molecule on antigen presenting cells, thereby inhibiting the co-
stimulatory pathway needed for activation of lymphocytes. A non-
randomised trial in GPA suggested an improvement on disease control 
and glucocorticoid sparing. The ABROGATE trial58 (n=150) is testing 
abatacept for glucocorticoid free remission induction in relapsing 
patients with non-severe GPA. 
 
MIRRA (Mepolizumab in EGPA) 
MIRRA (A Study to Investigate Mepolizumab in the Treatment of 
Eosinophilic Granulomatosis With Polyangiitis) trial (n=130) is currently 
recruiting patients with relapsing or refractory EGPA receiving standard 
of care therapy including background corticosteroid therapy with or 
without immunosuppressive therapy. Patients are randomised to receive 
either mepolizumab (300mg administered subcutaneously every 4 





 Improved understanding of the disease processes in the last decade has 
identified multiple new targets and strategies to treat this otherwise fatal 
disease. The development of tools to assess disease in vasculitis and experience 
with a sequence of clinical trials has established a foundation on which newer 
agents can be evaluated. Strategies to reduce toxicity associated with treatment 
whilst not compromising on the efficacy remains a key goal for future research. 
There is a need to optimise and customise the treatment for patients depending 
on disease severity and risk of relapse. This can be achieved by gaining further 
understanding of the pathogenesis and developing robust biomarkers. 
Subgrouping of patients according to ANCA serotype or disease severity may 
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